GlassScriptPhysician profile
Alberto Castiel
NPI 1386617082
$65,804.68
in general payments reported to CMS, 2019-2025
55 companies · $752 in 2025
The $752 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $3,624 · 2021: $2,400 · 2022: $1,671 · 2023: $12K · 2024: $1,336 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,765 · Food and Beverage: $3,777 · Travel and Lodging: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,765.00 |
| Food and Beverage | $3,777.45 |
| Travel and Lodging | $637.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $28,602.46 | 2019-2020 | |
| Osiris Therapeutics INC. | $13,782.63 | 2019 | |
| Idorsia Pharmaceuticals US INC | $10,848.07 | 2022-2024 | Quviviq |
| Novo Nordisk INC | $1,980.46 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $1,798.00 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,790.23 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $936.46 | 2019-2025 | Repatha, Evenity, Otezla |
| Janssen Pharmaceuticals, INC | $801.88 | 2019-2022 | |
| Antares Pharma, INC. | $545.64 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Abbott Laboratories | $413.82 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $363.40 | 2019-2025 | |
| Glaxosmithkline, LLC. | $363.40 | 2019-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $330.68 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $296.06 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $253.68 | 2019-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Castiel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.